Literature DB >> 27367418

Use of Androgen Deprivation Therapy With Radiotherapy for Intermediate- and High-Risk Prostate Cancer Across the United States.

Aaron D Falchook1, Ramsankar Basak1, Jahan J Mohiuddin1, Ronald C Chen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27367418     DOI： 10.1001/jamaoncol.2016.1143

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  3 in total

1.  Suboptimal use of hormonal therapy among German men with localized high-risk prostate Cancer during 2005 to 2015: analysis of registry data.

Authors:  Semaw Ferede Abera; Ahmed Bedir; André Glowka; Dirk Vordermark; Daniel Medenwald
Journal:  BMC Cancer       Date:  2022-06-07       Impact factor: 4.638

2.  Androgen-targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer.

Authors:  Gregory L Branigan; Georgina Torrandell-Haro; Maira Soto; Edward P Gelmann; Francesca Vitali; Kathleen E Rodgers; Roberta Diaz Brinton
Journal:  Cancer Med       Date:  2022-03-16       Impact factor: 4.711

3.  Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen.

Authors:  Jiang-Jiang Qin; Xin Li; Wei Wang; Xiaolin Zi; Ruiwen Zhang
Journal:  Front Pharmacol       Date:  2017-12-14       Impact factor: 5.810
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.